homehealthcare News

Reliance Life Sciences gets nod for Phase 1 trial of its COVID 19 vaccine candidate: Sources

Reliance Life Sciences gets nod for Phase 1 trial of its COVID-19 vaccine candidate: Sources

Reliance Life Sciences gets nod for Phase 1 trial of its COVID-19 vaccine candidate: Sources
Profile image

By CNBCTV18.com Aug 26, 2021 11:44:13 PM IST (Updated)

At present, India is administering three vaccines—Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin and Russia’s Sputnik V vaccine.

The Subject Expert Committee (SEC) on Thursday recommended Reliance Life Sciences to begin conducting Phase 1 clinical trial for its recombinant protein-based COVID-19 vaccine candidate, sources told CNBC-TV18.

Recommended Articles

View All

The aim of Phase I clinical trial is to obtain reliable information on safety, tolerability, pharmacokinetics (PK), and mechanism of action of drugs with the objective of determining the maximum tolerated dose (MTD).
Earlier this week, the Drugs Controller General of India (DCGI) granted approval for Phase 2 and 3 clinical trials of India's first mRNA COVID-19 vaccine candidate -- HGCO19 -- that is being developed by Genova Biopharmaceuticals.
At present, India is administering three vaccines—Serum Institute of India’s Covishield, Bharat Biotech’s Covaxin and Russia’s Sputnik V vaccine. Though US’ Moderna vaccine, Johnson and Johnson‘s single-dose vaccine and Zydus Cadila’s ZyCoV-D have received approval for emergency use, they are yet to be included in the nationwide inoculation drive.
Disclosure: Network18, the parent company of CNBCTV18.com, is controlled by Independent Media Trust, of which Reliance Industries is the sole beneficiary.
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!

Top Budget Opinions

    Most Read

    Market Movers

    View All
    Top GainersTop Losers
    CurrencyCommodities
    CompanyPriceChng%Chng